Table 1.
Patient baseline characteristics
| Number of patients | % of patients | |
|---|---|---|
| Median age: 56 years | ||
| Range: 26–86 years | ||
| Histology | ||
| Ductal carcinoma | 172 | 85.1 |
| Lobular carcinoma | 23 | 35.4 |
| Other | 7 | 3.5 |
| Subtype | ||
| Luminal A | 60 | 29.7 |
| Luminal B | 89 | 44.1 |
| HER2-enriched | 14 | 6.9 |
| TNBC | 39 | 19.3 |
| ER status | ||
| Positive | 145 | 71.8 |
| Negative | 57 | 28.2 |
| PgR status | ||
| Positive | 131 | 64.9 |
| Negative | 71 | 35.1 |
| HER2 status | ||
| Positive | 55 | 27.2 |
| Negative | 147 | 72.8 |
| Ki67 | ||
| < 20% | 74 | 36.6 |
| ≥ 20% | 127 | 62.9 |
| Unk | 1 | 0.5 |
| Stage | ||
| I | 42 | 20.8 |
| II | 111 | 55 |
| III | 49 | 24.3 |
| T stage | ||
| 1 | 64 | 31.7 |
| 2 | 89 | 44 |
| 3 | 21 | 10.4 |
| 4 | 27 | 13.4 |
| Unk | 1 | 0.5 |
| N stage | ||
| 0 | 101 | 50 |
| 1 | 82 | 40.6 |
| 2 | 10 | 5 |
| 3 | 6 | 3 |
| Unk | 3 | 1.4 |
| Tumor grade | ||
| G1 | 5 | 2.5 |
| G2 | 100 | 49.5 |
| G3 | 91 | 45 |
| Unk | 6 | 3 |
| Lymphovascular invasion | ||
| Yes | 41 | 20.3 |
| No | 156 | 77.2 |
| Unk | 5 | 2.5 |
| Neoadjuvant chemotherapy (NAC) | ||
| Yes | 126 | 72.4 |
| No | 76 | 37.6 |
| Type of NAC (N = 126) | ||
| EC → Taxane | 94 | 74.6 |
| FEC → Taxane | 21 | 16.7 |
| EC → CBDCA-Ptx | 6 | 4.8 |
| Other | 5 | 4 |
| Pathological complete response (N = 126) | ||
| Yes | 43 | 34.1 |
| No | 83 | 65.9 |
| Adjuvant chemotherapy (AC) | ||
| Yes | 43 | 21.3 |
| No | 159 | 78.7 |
| Type of AC (N = 43) | ||
| EC → Taxane | 11 | 25.6 |
| FEC → Taxane | 20 | 9.9 |
| Capecitabine | 5 | 11.6 |
| Other | 7 | 3.5 |
| Trastuzumab | ||
| Yes | 53 | 26.2 |
| No | 149 | 73.8 |
| Radiotherapy | ||
| Yes | 174 | 86.1 |
| No | 28 | 13.9 |
| Hormonotherapy | ||
| Yes | 149 | 73.2 |
| No | 54 | 26.8 |
| Type of hormonotherapy | ||
| SERM | 56 | 37.6 |
| AI | 79 | 53 |
| SERM + AI | 14 | 9.4 |
| Relapse | ||
| Yes | 28 | 13.9 |
| No | 174 | 86.1 |
TNBC triple-negative breast cancer, Unk unknown, NAC neoadjuvant chemotherapy, AC adjuvant chemotherapy, EC epirubicin–cyclophosphamide, FEC 5-fluorouracil–epirubicin–cyclophosphamide, CBDCA carboplatin, Ptx paclitaxel, N number of patients, SERM selective estrogen receptor modulator, AI aromatase inhibitor